Can we overcome resistance checkpoint blockade with novel approaches to DDR?
We still need to kill cancer cells to get durable complete responses - a look at ways to accomplish this feat
How can we use metabolic reprogramming to enhance CAR T cell therapy?
Rare mutations in lung cancer (STK11/KEAP1) could be associated with defects in cancer metabolism - we look how they impact KRAS mutant lung cancer
Can we influence T cell fitness and performance by manipulating metabolic processes?
In this post we’re taking a look at what we learnt about immunometabolism at AACR20 and some of the early signals from a cancer new product development perspective.
The aim of this post is to give you a sense of the potential of immunometabolism to impact T cell fate, fitness, and function.
A new emerging IO target of interest caught out attention, now what?
A novel epigenetic target may have far-reaching outcomes for cancer patients
A look at Kymera's protein degrader pipeline
If we were to tackle CAR T cell therapy design differently, how would we go about doing it?
Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...
Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?
Will we have more success targeting IL-18 to boost anti-tumour immunoty than other cytokines?
A look at some novel and promising approaches in early oncology new product development
Looking under the hood in NSCLC at underlying mutations and whether or not they impact survival
Highlights from various breast cancer trials and new pipeline developments
A look at Genentech's tiragolumab (anti-TIGIT) in advanced lung cancer
An in-depth look at the emerging SERD landscape in ER+ metastatic breast cancer
Does modality matter in oncology drug development and if so, where?
A look at what a young up and coming biotech in the TIGIT space are doing and how they see their approach being differentiated from the competition.
A raft of updates on the R&D pipelines in the adenosine niche, plus a biotech company interview
New developments in the DDR niche suggest a whole new approach to tackling solid tumours beyond women's cancers, pancreatic and prostate cancer might be feasible.
A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences
One particular presentation stood out from the others at AACR20 this year
In our latest postcard from AACR20 virtual meeting we take a look at the adoptive cell therapy plenary session
Commentary on Day 1 of the AACR20 Virtual Meeting
Why you should be wary of the hype surrounding the Iovance TIL data in NSCLC at AACR20
Ten intriguing novel agents in early development to watch out for
Beyond KRAS G12C inhibitors, there are plenty of other related targets to consider including KRAS::SOS1 and SHP2
A look at a wide array of targets, modalities, new agents and companies through the lens of targeted therapies
What to watch out for at AACR20 - the first of our meeting previews is here!
A look at the revised schedule and timelines for upcoming Spring cancer conference season
Where are they now four years on? A look at the BET/Bromodomain landscape
Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?
Key RNA transcription factors may have a role to play as therapeutic targets for both cancer treatment and the coronavirus
